Peringatan Keamanan

Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.

Dienestrol

DB00890

small molecule approved investigational

Deskripsi

Dienestrol is a synthetic, non-steroidal estrogen. It is an estrogen receptor agonist. Estrogens work partly by increasing a normal clear discharge from the vagina and making the vulva and urethra healthy. Using or applying an estrogen relieves or lessens: dryness and soreness in the vagina, itching, redness, or soreness of the vulva. Conditions that are treated with vaginal estrogens include a genital skin condition (vulvar atrophy), inflammation of the vagina (atrophic vaginitis), and inflammation of the urethra (atrophic urethritis).

Struktur Molekul 2D

Berat 266.34
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Systemic absorption and mode of action of dienestrol are undetermined.Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).

Metabolisme

Hepatic.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

413 Data
Prasterone The risk or severity of adverse effects can be increased when Prasterone is combined with Dienestrol.
Exemestane The therapeutic efficacy of Exemestane can be decreased when used in combination with Dienestrol.
Lenalidomide Dienestrol may increase the thrombogenic activities of Lenalidomide.
Ospemifene The risk or severity of adverse effects can be increased when Dienestrol is combined with Ospemifene.
Ropinirole Dienestrol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.
Thalidomide Dienestrol may increase the thrombogenic activities of Thalidomide.
Cetuximab Dienestrol may increase the thrombogenic activities of Cetuximab.
Human immunoglobulin G Dienestrol may increase the thrombogenic activities of Human immunoglobulin G.
Omalizumab Dienestrol may increase the thrombogenic activities of Omalizumab.
Adalimumab Dienestrol may increase the thrombogenic activities of Adalimumab.
Abciximab Dienestrol may increase the thrombogenic activities of Abciximab.
Gemtuzumab ozogamicin Dienestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.
Indium In-111 satumomab pendetide Dienestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.
Infliximab Dienestrol may increase the thrombogenic activities of Infliximab.
Trastuzumab Dienestrol may increase the thrombogenic activities of Trastuzumab.
Rituximab Dienestrol may increase the thrombogenic activities of Rituximab.
Basiliximab Dienestrol may increase the thrombogenic activities of Basiliximab.
Muromonab Dienestrol may increase the thrombogenic activities of Muromonab.
Digoxin Immune Fab (Ovine) Dienestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).
Ibritumomab tiuxetan Dienestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.
Tositumomab Dienestrol may increase the thrombogenic activities of Tositumomab.
Alemtuzumab Dienestrol may increase the thrombogenic activities of Alemtuzumab.
Capromab pendetide Dienestrol may increase the thrombogenic activities of Capromab pendetide.
Efalizumab Dienestrol may increase the thrombogenic activities of Efalizumab.
Antithymocyte immunoglobulin (rabbit) Dienestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).
Natalizumab Dienestrol may increase the thrombogenic activities of Natalizumab.
Palivizumab Dienestrol may increase the thrombogenic activities of Palivizumab.
Daclizumab Dienestrol may increase the thrombogenic activities of Daclizumab.
Bevacizumab Dienestrol may increase the thrombogenic activities of Bevacizumab.
Technetium Tc-99m arcitumomab Dienestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.
Eculizumab Dienestrol may increase the thrombogenic activities of Eculizumab.
Panitumumab Dienestrol may increase the thrombogenic activities of Panitumumab.
Ranibizumab Dienestrol may increase the thrombogenic activities of Ranibizumab.
Galiximab Dienestrol may increase the thrombogenic activities of Galiximab.
Pexelizumab Dienestrol may increase the thrombogenic activities of Pexelizumab.
Afelimomab Dienestrol may increase the thrombogenic activities of Afelimomab.
Epratuzumab Dienestrol may increase the thrombogenic activities of Epratuzumab.
Bectumomab Dienestrol may increase the thrombogenic activities of Bectumomab.
Oregovomab Dienestrol may increase the thrombogenic activities of Oregovomab.
IGN311 Dienestrol may increase the thrombogenic activities of IGN311.
Adecatumumab Dienestrol may increase the thrombogenic activities of Adecatumumab.
Labetuzumab Dienestrol may increase the thrombogenic activities of Labetuzumab.
Matuzumab Dienestrol may increase the thrombogenic activities of Matuzumab.
Fontolizumab Dienestrol may increase the thrombogenic activities of Fontolizumab.
Bavituximab Dienestrol may increase the thrombogenic activities of Bavituximab.
CR002 Dienestrol may increase the thrombogenic activities of CR002.
Rozrolimupab Dienestrol may increase the thrombogenic activities of Rozrolimupab.
Girentuximab Dienestrol may increase the thrombogenic activities of Girentuximab.
Obiltoxaximab Dienestrol may increase the thrombogenic activities of Obiltoxaximab.
XTL-001 Dienestrol may increase the thrombogenic activities of XTL-001.
NAV 1800 Dienestrol may increase the thrombogenic activities of NAV 1800.
Briakinumab Dienestrol may increase the thrombogenic activities of Briakinumab.
Otelixizumab Dienestrol may increase the thrombogenic activities of Otelixizumab.
AMG 108 Dienestrol may increase the thrombogenic activities of AMG 108.
Iratumumab Dienestrol may increase the thrombogenic activities of Iratumumab.
Enokizumab Dienestrol may increase the thrombogenic activities of Enokizumab.
Ramucirumab Dienestrol may increase the thrombogenic activities of Ramucirumab.
Farletuzumab Dienestrol may increase the thrombogenic activities of Farletuzumab.
Veltuzumab Dienestrol may increase the thrombogenic activities of Veltuzumab.
Ustekinumab Dienestrol may increase the thrombogenic activities of Ustekinumab.
Trastuzumab emtansine Dienestrol may increase the thrombogenic activities of Trastuzumab emtansine.
PRO-542 Dienestrol may increase the thrombogenic activities of PRO-542.
TNX-901 Dienestrol may increase the thrombogenic activities of TNX-901.
Inotuzumab ozogamicin Dienestrol may increase the thrombogenic activities of Inotuzumab ozogamicin.
RI 624 Dienestrol may increase the thrombogenic activities of RI 624.
Stamulumab Dienestrol may increase the thrombogenic activities of MYO-029.
CT-011 Dienestrol may increase the thrombogenic activities of CT-011.
Leronlimab Dienestrol may increase the thrombogenic activities of Leronlimab.
Glembatumumab vedotin Dienestrol may increase the thrombogenic activities of Glembatumumab vedotin.
Olaratumab Dienestrol may increase the thrombogenic activities of Olaratumab.
IPH 2101 Dienestrol may increase the thrombogenic activities of IPH 2101.
TB-402 Dienestrol may increase the thrombogenic activities of TB-402.
Caplacizumab Dienestrol may increase the thrombogenic activities of Caplacizumab.
IMC-1C11 Dienestrol may increase the thrombogenic activities of IMC-1C11.
Eldelumab Dienestrol may increase the thrombogenic activities of Eldelumab.
Lumiliximab Dienestrol may increase the thrombogenic activities of Lumiliximab.
Canakinumab Dienestrol may increase the thrombogenic activities of Canakinumab.
Ipilimumab Dienestrol may increase the thrombogenic activities of Ipilimumab.
Nimotuzumab Dienestrol may increase the thrombogenic activities of Nimotuzumab.
Clenoliximab Dienestrol may increase the thrombogenic activities of Clenoliximab.
Tocilizumab Dienestrol may increase the thrombogenic activities of Tocilizumab.
BIIB015 Dienestrol may increase the thrombogenic activities of BIIB015.
Sonepcizumab Dienestrol may increase the thrombogenic activities of Sonepcizumab.
Motavizumab Dienestrol may increase the thrombogenic activities of Motavizumab.
Elotuzumab Dienestrol may increase the thrombogenic activities of Elotuzumab.
AVE9633 Dienestrol may increase the thrombogenic activities of AVE9633.
Carotuximab Dienestrol may increase the thrombogenic activities of Carotuximab.
XmAb 2513 Dienestrol may increase the thrombogenic activities of XmAb 2513.
Coltuximab ravtansine Dienestrol may increase the thrombogenic activities of Coltuximab ravtansine.
Lucatumumab Dienestrol may increase the thrombogenic activities of Lucatumumab.
Pertuzumab Dienestrol may increase the thrombogenic activities of Pertuzumab.
Siplizumab Dienestrol may increase the thrombogenic activities of Siplizumab.
Apolizumab Dienestrol may increase the thrombogenic activities of Apolizumab.
Sibrotuzumab Dienestrol may increase the thrombogenic activities of Sibrotuzumab.
Bivatuzumab Dienestrol may increase the thrombogenic activities of Bivatuzumab.
Lerdelimumab Dienestrol may increase the thrombogenic activities of Lerdelimumab.
Lexatumumab Dienestrol may increase the thrombogenic activities of Lexatumumab.
Reslizumab Dienestrol may increase the thrombogenic activities of Reslizumab.
Teplizumab Dienestrol may increase the thrombogenic activities of Teplizumab.
Catumaxomab Dienestrol may increase the thrombogenic activities of Catumaxomab.

Target Protein

Estrogen receptor ESR1
Sex hormone-binding globulin SHBG

Referensi & Sumber

Synthesis reference: Short, W.F. and Hobday, G.1; U.S. Patent 2,464,203; March 15,1949; assigned to Boots Pure Drug Company Limited, England. Adler, E.; U.S. Patent 2,465,505; March 29,1949; assigned to Hoffmann-La Roche Inc.

Contoh Produk & Brand

Produk: 1 • International brands: 7
Produk
  • Ortho Dienestrol Crm
    Cream • .01 % • Vaginal • Canada • Approved
International Brands
  • Estraguard
  • Estroral
  • Ortho Dienestrol — Ortho-McNeil Pharmaceutical
  • Restrol
  • Retalon
  • Sexadien — LEO Pharma A/S
  • Synestrol

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul